Ferroptosis: At the Crossroad of Gemcitabine Resistance and Tumorigenesis in Pancreatic Cancer

The overall five-year survival rate of pancreatic cancer has hardly changed in the past few decades (less than 10%) because of resistance to all known therapies, including chemotherapeutic drugs. In the past few decades, gemcitabine has been at the forefront of treatment for pancreatic ductal adenoc...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Jianhui, Xu, Jin, Zhang, Bo, Tan, Zhen, Meng, Qingcai, Hua, Jie, Liu, Jiang, Wang, Wei, Shi, Si, Yu, Xianjun, Liang, Chen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8539929/
https://www.ncbi.nlm.nih.gov/pubmed/34681603
http://dx.doi.org/10.3390/ijms222010944

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8539929/
https://www.ncbi.nlm.nih.gov/pubmed/34681603
http://dx.doi.org/10.3390/ijms222010944

Ejemplares similares